Lactic Acid Bacteria Coaggregation for Wound Biofilm Inhibition
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for wound infections and skin diseases caused by Staphylococcus aureus and Pseudomonas aeruginosa, such as chronic wounds, are often ineffective due to the bacteria's ability to form biofilms, leading to prolonged healing times and increased resistance to antibiotics, particularly in immunocompromised patients.
Innovation Solution
The use of specific lactic acid bacteria strains from the DSM collection, or their derivatives, which can coaggregate with Staphylococcus aureus and Pseudomonas aeruginosa, reducing their local concentration, inhibiting growth, and preventing biofilm formation, offering a non-antibiotic alternative for treatment.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If antibiotic therapy is used to treat wound infections caused by Staphylococcus aureus and Pseudomonas aeruginosa, then bacterial growth is inhibited, but antibiotic resistance develops and treatment effectiveness decreases
Solution Approach 1:
The patent employs lactic acid bacteria as intermediary organisms that naturally coaggregate with pathogenic bacteria (Staphylococcus aureus and Pseudomonas aeruginosa). These probiotic bacteria bind to the pathogenic bacteria through cell surface interactions, forming aggregates that prevent the pathogens from adhering to wound tissue and forming biofilms. This intermediary approach eliminates the need for direct antibiotic application, thereby avoiding resistance development while maintaining treatment effectiveness.
2Reliability
If lactic acid bacteria are used to coaggregate with pathogenic bacteria, then bacterial load is reduced and biofilm formation is prevented, but the mechanism of action requires further clarification
Solution Approach 1:
The lactic acid bacteria possess inherent coaggregation capabilities through their cell surface structures, allowing them to naturally bind to pathogenic bacteria without requiring external agents or complex activation processes. The bacteria perform their anti-pathogenic function autonomously through this self-service mechanism, where their natural biological properties enable them to reduce bacterial load and prevent biofilm formation in wound environments.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach effectively reduces the bacterial load, inhibits biofilm formation, and accelerates wound healing without inducing antibiotic resistance, providing a cost-effective and safer treatment option for skin infections and wounds.
Implementation Method 1
the microorganism, or cell lysate, derivative, mutant or combination thereof is capable of coaggregating with at least one pathogenic microorganism
Implementation Method 2
the at least one pathogenic microorganism is capable of coaggregating even after biological, chemical or physical treatment
Data Source
AI summary
The invention relates to a microorganism, of the order of lactic acid bacteria or analog, fragment, derivative, mutant or combination thereof. Said microorganism, or analog, fragment, derivative, mutants or combination thereof can be co-aggregated with at least Staphylococcus aureus or Pseudomonas aeruginosa.